clinical trial · NCT07196124
BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma
Guangzhou Bio-gene Technology Co., Ltd·early phase1·not yet recruiting·n = 12
Multiple Myeloma RefractoryBCMA/GPRC5D CAR-T
brief summary
This study is a single-arm, multicenter clinical trial of dose escalation and dose expansion.
started
Oct 10, 2025
primary completion
Oct 9, 2028
completion
Dec 9, 2028
last updated
Sep 29, 2025
detailed description
This study is a single-arm, mult-center clinical trial of dose escalation and dose expansion, primarily aimed at evaluating the safety, tolerability, and preliminary efficacy of BCMA/GPRC5D CAR-T cell infusion in subjects with relapsed/refractory multiple myeloma.
official title
Clinical Study Evaluating the Safety and Efficacy of BCMA/GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol